Cancer Type/Condition: Leukemia, acute myeloid (AML), adult
Stage/Subtype: recurrent adult acute myeloid leukemia
Country: U.S.A.
Trial Type: Treatment
Trial Status: Active
1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: MCC-14178, NCT00361140
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 to 70
Sponsor: Other
Protocol IDs: RPCI-RP-9815, NCI-V99-1527, NCT00003816, RP 98-15
|
|
3.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0358, NCT00398983
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 12 to 55
Sponsor: Pharmaceutical / Industry
Protocol IDs: GC P#02.01.001, NCT00469729
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI
Protocol IDs: FHCRC-1813.00, 5666, NCT00075478
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E2902, E2902, NCT00093470
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: NCI, NHLBI
Protocol IDs: FHCRC-1992.00, 6170, NCT00322101, NHLBI-K23-HL084054-01A1
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLO34100405, NCT00317642
|
|
10.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 65 and under
Sponsor: Other
Protocol IDs: 2005-0366, NCT00469144
|
|
11.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 2 to 55
Sponsor: NCI, NHLBI
Protocol IDs: 385, BMT CTN 0402, U01 HL069294-05, NCT00406393
|
|
12.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 75 and under
Sponsor: NCI
Protocol IDs: FHCRC-1655.00, 5430, NCT00052520
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: FHCRC-1803.00, 5606, NCT00068718
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: H8713, NCT00058825
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 to 50
Sponsor: Other
Protocol IDs: FHCRC-1809.00, 5602, NCT00119366
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: OHSU-HEM-05011-L, OHSU-210, NCT00245037
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-065, X05175, NCT00369226
|
|
18.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: S-WHITE-22304, 50047, S-WHITE-050047, NCT00397579
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NYCC-6898, 6898, NCI-6898, NCT00392353
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: 2005-0508, NCT00402558
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 55
Sponsor: NCI
Protocol IDs: MSKCC-06125, NCT00423514
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP4055-106, NCT00405743
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 06U.70, X05193, NCT00410423
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 04U.115, NCT00429416
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PDX-009, NCT00481871
|
